longer-term follow-up on frontline io and tki studies and impacts to treatment selection
Published 8 months ago • 25 plays • Length 9:01Download video MP4
Download video MP3
Similar videos
-
9:16
frontline rcc treatment selection: io/io versus io/tki
-
6:45
the latest data on io/tki versus io/io in frontline rcc
-
7:57
patient selection for io/io versus io/tki in the frontline setting
-
10:04
drs. rini, plimack discuss the latest frontline io/tki data in rcc from 2023 asco® annual meeting
-
4:57
review of the data of frontline treatment for non-clear cell kidney cancer
-
5:33
cancer immune checkpoint inhibitors
-
1:18:47
"tkis: tyrosine kinase inhibitors & neuroendocrine tumors" • 2024 lacnets event • march 29, 2024
-
1:02
killer t cell attacking cancer
-
1:28
comparing io/tki and tki monotherapy for kidney cancer
-
5:47
asco® gu data updates in frontline kidney cancer: was anything practice changing?
-
42:06
the uromigos: frontline therapy in rcc
-
4:23
second-line treatment options for rcc
-
26:09
front-line therapy in papillary renal cancer: uromigos live 2024
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
-
0:16
activated t cell attacks a cancer cell
-
4:49
frontline tki strategies in kidney cancer
-
22:33
2022 west oncology conference | genitourinary cancers | kidney session
-
9:52
factors in selecting immunotherapy or tki inhibition
-
1:02:22
individualizing rcc therapy in the era of immuno-oncology
-
0:34
io-io and io-tki treatments could improve 5-year survival rate for arcc
-
8:57
advanced renal cell carcinoma: managing long term durable response
-
1:05:05
hcc: optimizing outcomes with new and emerging treatment approaches